Pönisch, Wolfram <br/><br/>
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.  [electronic resource] 

 -  Journal of cancer research and clinical oncology  Nov 2013 
 - 1937-46 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-1335 
<br/><br/><label>Standard No.: </label>10.1007/s00432-013-1513-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bendamustine Hydrochloride<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Female<br/>Glomerular Filtration Rate<br/>Humans<br/>Immunoglobulin Light Chains--immunology<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Staging<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Prednisone--administration & dosage<br/>Pyrazines--administration & dosage<br/>Renal Insufficiency--immunology<br/>Retrospective Studies